Advancing the Treatment Landscape for Lower-Risk MDS: Unmet Needs and Future Directions

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory follicular lymphoma.

The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, particularly benefiting patients 60 and older.

“We have seen a number of dynamic changes in MDS over the last few years, and integrating them into our treatment paradigm will impact our approach, and perhaps offer a glimpse into the future."

David Sallman, MD, discussed the challenges and new studies of high-risk myelodysplastic syndrome therapies.

Janelle Vicens, DNP, APRN, FNP-BC, and Sandra Sepulveda, AGPNP-BC, MSN, BMTCN, discussed what went into developing this Malignant Hematology and Bone Marrow Transplant APP Fellowship.

During a Case-Based Roundtable® event, Yazan Madanat, MD, discussed a the patient population and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in the first article of a 2-part series.